Innovent Biologics, Inc.

SEHK:1801 Rapporto sulle azioni

Cap. di mercato: HK$64.7b

Innovent Biologics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Innovent Biologics has a total shareholder equity of CN¥12.4B and total debt of CN¥3.2B, which brings its debt-to-equity ratio to 25.8%. Its total assets and total liabilities are CN¥20.3B and CN¥7.9B respectively.

Informazioni chiave

25.8%

Rapporto debito/patrimonio netto

CN¥3.21b

Debito

Indice di copertura degli interessin/a
ContantiCN¥8.63b
Patrimonio nettoCN¥12.43b
Totale passivitàCN¥7.87b
Totale attivitàCN¥20.30b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Jun 14
Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 01
Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Feb 28
There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Jan 12
Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

Dec 25
Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Sep 11
An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Jun 04
Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

May 14
Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Dec 27
Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Analisi della posizione finanziaria

Passività a breve termine: 1801's short term assets (CN¥11.0B) exceed its short term liabilities (CN¥4.1B).

Passività a lungo termine: 1801's short term assets (CN¥11.0B) exceed its long term liabilities (CN¥3.7B).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 1801 has more cash than its total debt.

Riduzione del debito: 1801's debt to equity ratio has increased from 22.7% to 25.8% over the past 5 years.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 1801 has sufficient cash runway for more than 3 years based on its current free cash flow.

Previsione Cash Runway: Insufficient data to determine if 1801 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Scoprire le aziende sane